<DOC>
	<DOCNO>NCT01685268</DOCNO>
	<brief_summary>A 2-part , Phase 1-2 , open-label , parallel group , randomize study patient Castration-Resistant Prostate Cancer ( CRPC ) longer respond treatment abiraterone steroid . In Part A ( Phase 1 ) , patient continue receive dos abiraterone steroid receive prior study entry randomize receive 1 2 different treatment regimen AT13387 combination abiraterone . Once best regimen establish Part A , base safety antitumor activity , patient randomize select treatment regimen dose AT13387 combination abiraterone AT13387 alone Part B ( Phase 2 ) .</brief_summary>
	<brief_title>A Study HSP90 Inhibitor AT13387 Alone Combination With Abiraterone Acetate</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Inclusion : 1 . Must prostate cancer 2 . Have receive prior castration orchiectomy and/or hormone therapy 3 . Males &gt; 18 year age 4 . Normal activity level self care 5 . Have receive abiraterone therapy steroid â‰¥1 month 6 . Have disease progression abiraterone define either PSA progression , radiographic bone progression 7 . Have adequate bone marrow , liver kidney function 8 . Must willing provide preexist tumor sample , material exists . If preexisting sample available , sample must obtain screen 9 . Must willing able provide write informed consent comply protocol study procedure Exclusion : 1 . Prior anticancer treatment Heat Shock Protein 90 ( HSP90 ) inhibitor histone deacetylase ( HDAC ) inhibitor compound 2 . Have receive chemotherapy within 4 week prior receive study drug 3 . Prior prostate surgery radiotherapy within 4 week first dose study drug 4 . Hypersensitivity AT13387 component drug product 5 . Treatment investigational drug within 4 week prior first dose study drug 6 . Severe systemic disease active uncontrolled infection 7 . Presence lifethreatening illness , medical condition , organ system dysfunction , factor 8 . Abnormal heart function 9 . Other cancer except adequately treat basal cell squamous cell carcinoma skin , superficial bladder cancer , cancer subject diseasefree least 3 year ; 10 . No known brain CNS involvement 11 . Unable receive corticosteroid history pituitary adrenal dysfunction 12 . Known history human immunodeficiency virus ( HIV ) seropositive test hepatitis C virus hepatitis B virus</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
</DOC>